2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

455 Combination screening identifies the RAS(ON) inhibitor daraxonrasib as a synergistic partner to overcome 5-azacitidine-venetoclax resistance in acute myeloid leukemia

Eric O'Brien, MBA, Mithun Sarangdhar, Ph.D.2, Brett VanCauwenbergh3, Mitali Basu4, Gabriel Wahler5, LaQuita M Jones, DO6, John Perentesis, MD7
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
6 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
7 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Background

Although 5-Azacitidine and Venetoclax (Aza-Ven) have transformed Acute Myeloid Leukemia (AML) therapy, clinical durability is frequently limited by primary and acquired resistance driven by compensatory RAS/MAPK pathway activation. Daraxonrasib is a first-in-class, noncovalent RAS(ON) multi-selective inhibitor that overcomes traditional single-mutation constraints by engaging cyclophilin A (CypA) to form a tri-complex (CypA–Daraxonrasib–RAS). This assembly creates a bulky steric barrier that physically occludes downstream effector binding (e.g., RAF) across multiple active/on, GTP-bound RAS variants. Leveraging this unique pan-RAS steric blockade, we performed unbiased high-throughput single agent and combination screening in 37 cell lines and patient samples to identify Daraxonrasib sensitive lines and those that would benefit from the combination of Aza-Ven+Daraxonrasib. Daraxonrasib was tested against a genetically diverse panel encompassing canonical hotspot mutations (NRAS G12D/G13D/Q61L, KRAS Q61H), upstream drivers (FLT3-ITD, KIT N822K), and fusion-driven leukemias including KMT2A::MLLT4 (MLL-AF6), whose wild-type MLLT4 RAS-associating RA1 domain directly binds active RAS.

Methods

Daraxonrasib was systematically evaluated across 37 genetically diverse cell lines (29 AML, 3 B-ALL, 5 rhabdomyosarcoma [RMS]) as a single agent and in combination with Aza-Ven. Additionally, a 113-compound screen was conducted in combination with a fixed 1:10 Aza-Ven molar ratio backbone across six AML cell lines.  Pharmacologic profiling consisted of single-agent dose–response assays (0.02–10,000 nM) and Daraxonrasib-Aza-Ven 8x8 combination matrices. Drug synergy was quantified using ΔBliss where 0 denotes additivity and the more negative the values are denotes greater synergy.

Results

Daraxonrasib ranked first among 113 compounds (mean ΔBliss, -11.81), followed by the MCL-1 inhibitors MIK665 (-11.05) and AZD-5991 (-10.95). Across 29 AML models, median single-agent IC50 was 254 nM (range, 4.1 to ≥10,000), and 13/29 (44.8%) had IC50 ≤100 nM. All 29 models had negative combination scores (median, -7.16; range, - 23.98 to -1.28), and 12/29 (41.4%) had scores ≤-10. Cell lines with single-agent IC50 ≤100 nM (n=13) had a median 3.46-fold potency shift and median ΔBliss of -5.93, whereas models with IC50 ≥1,000 nM (n=13) showed a median 70.5-fold shift and median ΔBliss of -10.51, consistent with Aza-Ven creating resistance signaling through the RAS/MAPK pathway that can be targeted with RAS(ON) inhibition. Direct RAS-mutant AML models (n=11) had a median ΔBliss of -13.88, with all scores ≤-5 despite heterogeneous single-agent potency. NB-4 (KRAS A18D) showed an incomplete-killing plateau with Daraxonrasib alone but the strongest combination interaction (ΔBliss, -23.98; 637-fold potency shift), consistent with a cytostatic-like single-agent response. B-ALL comparators had IC50 ≥10,000 nM and minimal potency shifts (1.0-1.25-fold). PAX3-FOXO1 RMS models showed no measurable single-agent response or combination potentiation (IC50 ≥10,000 nM; fold shift, 1; ΔBliss ≥0), whereas NRAS Q61H RMS (RD) was single-agent sensitive (IC50, 200 nM) but not combination-potentiated, supporting treatment- and lineage-context dependence. Among three models annotated as KMT2A::MLLT4, CTS and SHI-1 had low-nanomolar single-agent IC50 values (4.1 and 12.6 nM); 2022-178-H was insensitive alone but sensitized with Aza-Ven (combination-associated IC50, 11.7 nM; 855-fold shift; ΔBliss, -18.61).

Conclusions

Daraxonrasib emerged as a top enhancer of Aza-Ven, ranking above MCL-1 inhibitors and avoiding their associated cardiotoxicities, while demonstrating broad combination synergy across AML models including robust potency shifts in single-agent-resistant phenotypes.  Low nM single agent Daraxonrasib IC50’s were observed in receptor tyrosine kinases such as FLT3-ITD and KIT mutant AML lines whose signaling is upstream of RAS.  This same level of potency was also observed in several BCR-ABL1 and KMT2A::MLLT4 fusion driven cell lines.  These findings highlight translational strategies leveraging RAS(ON) inhibition with Daraxonrasib to treat RAS mutant and RAS/MAPK pathway activating mutations and to mitigate RAS/MAPK signaling resistance to Aza-Ven in AML. Overall, these results warrant mechanistic and functional validation of Daraxonrasib plus Aza-Ven to support future clinical development in AML.
Eric O'Brien, MBA: No relevant conflicts of interest to declare.